A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

NCT03773666 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Muscle Invasive Bladder Cancer

Interventions

DRUG: Durvalumab
DRUG: Oleclumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]